SCHEMBL8736593

SCHEMBL8736593

NC1=NCc2c(F)cccc21

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.50
NOS2 P35228 4/20 0.47
NOS3 P29474 4/20 0.47
TSHR P16473 1/20 0.47
TYMS P04818 1/20 0.38
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HDAC8 Q9BY41 2/20 0.35
NISCH Q9Y2I1 1/20 0.34
MPL P40238 1/20 0.34
CYP19A1 P11511 2/20 0.33
GRM5 P41594 1/20 0.33
GRM1 Q13255 1/20 0.33
MAPK1 P28482 1/20 0.33
DRD2 P14416 1/20 0.33
DRD3 P35462 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29282154 0.72 TSHR (0.43) HTR5ANOS2NOS3TSHR
SCHEMBL9949264 0.68 HTR5A (0.51) HTR5ANOS2NOS3TSHRHDAC8
SCHEMBL4666252 0.67 TYMS (0.46) HTR5ANOS2NOS3TYMSKDM4E
SCHEMBL5684576 0.66 PGR (0.47) HTR5ANOS2NOS3TYMSNISCH
SCHEMBL29517854 0.66 PGR (0.47) HTR5ANOS2NOS3TYMSNISCH
SCHEMBL31703623 0.66 TSHR (0.95) HTR5ANOS2NOS3TSHRKDM4E
SCHEMBL1194687 0.66 TSHR (0.95) HTR5ANOS2NOS3TSHRKDM4E
Hydrochloric Acid SCHEMBL4092945 0.64 TSHR (1.00) HTR5ANOS2NOS3TSHRKDM4E
Hydrochloric Acid SCHEMBL29386664 0.64 TSHR (1.00) HTR5ANOS2NOS3TSHRKDM4E
SCHEMBL8487986 0.62 NOS2 (0.52) HTR5ANOS2NOS3TSHRTYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2640731-B9 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2015-11-25 EP disclosed
EP-2640731-B1 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS LUNDBECK & CO AS H (DK) 2015-07-08 EP disclosed
US-9062060-B2 Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors H. LUNDBECK A/S (DK) 2015-06-23 US disclosed
US-9062060-B2 Substituted imidazo[2,1-A]isoindoles as PDE10 inhibitors H. LUNDBECK A/S (DK) 2015-06-23 US disclosed
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors H. LUNDBECK A/S (DK) 2014-12-04 US disclosed
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors H. LUNDBECK A/S (DK) 2014-12-04 US disclosed
US-8796304-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2014-08-05 US disclosed
US-8796304-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2014-08-05 US disclosed
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-8552045-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2013-10-08 US disclosed
US-8552045-B2 Tricyclic imidazole compounds as PDE10 inhibitors H. LUNDBECK A/S (DK) 2013-10-08 US disclosed
WO-2013045607-A1 QUINAZOLINE LINKED HETEROAROMATIC TRICYCLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2013-04-04 WO disclosed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed
US-20120129836-A1 Imidazole derivatives as PDE10A enzyme inhibitors H. LUNDBECK A/S (DK) 2012-05-24 US disclosed
US-20120129836-A1 Imidazole derivatives as PDE10A enzyme inhibitors H. LUNDBECK A/S (DK) 2012-05-24 US disclosed
WO-2012065612-A1 IMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS H. LUNDBECK A/S (DK) 2012-05-24 WO disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129836-A1 Imidazole derivatives as PDE10A enzyme inhibitors PDE5A, PDE3A, PDE3B HTR5A 96/4885NOS2 268/4885NOS3 395/4885
US-20140357639-A1 Imidazole derivatives as PDE10 enzyme inhibitors PDE12, PDE5A, PDE10A HTR5A 213/4885NOS2 158/4885NOS3 279/4885
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 HTR5A 3335/4885NOS2 1695/4885NOS3 1625/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 HTR5A 2788/4885NOS2 2918/4885NOS3 836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.